Bevacizumab in Treating Patients With Myelodysplastic Syndrome

Part of paid clinical trials in Tucson, Arizona.

Sponsor
Stanford University
Study ID
NCT00022048
Phase
PHASE1/PHASE2
Status
Completed

Conditions

  • Leukemia
  • Myelodysplastic Syndromes
  • Myelodysplastic/Myeloproliferative Neoplasms

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

RATIONALE: Monoclonal antibodies, such as bevacizumab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or deliver cancer-killing substances to them. PURPOSE: This phase I/II trial is to see if bevacizumab works in treating patients who have myelodysplastic syndrome.

Key Dates

First listed
Jan 27, 2003
Start date
Aug 31, 2001
Status verified
Oct 2004
Completion
Nov 30, 2004

Study Design

Primary purpose
TREATMENT

Locations (3)

FacilityCityStateZIPSite coordinators
Arizona Cancer Center at University of Arizona Health Sciences CenterTucsonArizona85724-
Stanford Cancer Center at Stanford University Medical CenterStanfordCalifornia94305-5750-
University of Texas - MD Anderson Cancer CenterHoustonTexas77030-4009-

Find similar trials in Tucson, AZ

By condition
Leukemia (other)
By specialty
OncologyBlood cancer
By research site
Arizona Cancer Center at University of Arizona Health Sciences Center· Tucson, AZStanford Cancer Center at Stanford University Medical Center· Stanford, CAUniversity of Texas - MD Anderson Cancer Center· Houston, TX

Related Studies